舒血宁合并抗精神病药物治疗慢性精神分裂症的对照研究

作者	单位
罗和春
沈渔
孟凡强
王洪灏
于江
伊吉林
刘广志
钟红文
张本
陆玲林
杨富收
张淑芹
马启民
张永恒
朱连成
朱美兰
朱少敏
陈钊

摘要点击次数: 1333

全文下载次数: 1098

中文摘要:

目的：评价舒血宁对于慢性精神分裂症的疗效。方法：采用双盲对照多中心（全国１６家医院）协作的方法，共纳入５４５例慢性精神分裂症患者，在原抗精神病药物治疗稳定３个月的基础上，被随机分为舒血宁治疗组（舒血宁１２０ｍｇ，每天３次）或对照组。治疗时间为１６周。结果：从治疗的第６周起，舒血宁治疗组的简明精神病评定量表（ＢＰＲＳ）和阴性症状评定量表（ＳＡＮＳ）评分的降低显著大于对照组（Ｐ＜０．０１）；舒血宁组对于ＢＰＲＳ的迟滞因子和思维障碍因子的疗效显著优于对照组；根据传统疗效评定标准分析，舒血宁组治疗的显效率显著高于对照组，分别为４４．９８％和２０．９８％（Ｐ＜０．０１）；治疗中两组患者的药物副反应无显著性差异。结论：舒血宁是一个与抗精神病药物合并应用治疗慢性精神分裂症的有效药物。在每日３６０ｍｇ的剂量范围内无明显不良药物反应。

英文摘要:

To assess the therapeutic effect of Shuxuening (SXN), the extractum of Ginkgo biloba 761 (EGb761 ) in treating chronic schizophrenia. Methods: A double-blind, placebo-controlled multi-center research on the treatment of chronic schizophrenics with SXN was used. Five hundred and forty-five patients were randomly divided into either SXN group or the control group. Patients in the former group received SXN 120 mg three times daily. Patients in both groups received their maintenance neuroleptics throughout the 16-week research treatment. Results: The patients’ rating scores of brief psychiatric rating scale (BPRS) and Scale for the Assessment of Negative Symptoms reduced much greater in SXN group than those in the control group from the sixth week of treatment (P<0. 01 ). The effect of SXN for BPRS factors of retardation and thought disturbance was better than that of the control. SXN presented a better therapeutic effect for chronic schizophrenics than the control when rated with traditional global rating method as well, in which 44. 98 % marked improvement was obtained in SXN group compared to 20. 98% in the control group. Conclusion: SXN combining neuroleptics , was an effective medicine for chronic schizophrenics, Moreover, it appeared few side-effects within the recommended dose range.

关闭